Physiomics plc
Physiomics Plc is an AIM-listed Oxfordshire-based company providing outsourced consulting and contract research services to biopharmaceutical companies and research institutes, principally in Modelling & Simulation (quantitative pharmacology) and, from FY26, Biometrics (biostatistics, statistical programming and data management), supported by its proprietary Virtual Tumour software platform. It also develops a personalised-medicine dosing technology (funded largely by Innovate UK/NIHR grants) aimed at predicting optimal cancer drug dosing. The company operates a fee-for-service consulting business model and is loss-making but cash generative enough to fund operations alongside periodic equity fundraises.
FY2026 in sixty seconds
year to 30 Jun 2026 · approved 12 Oct 2026 · 61 pages · Companies House
Physiomics Plc, which sells computer modelling and statistics services to drug developers, saw revenue rise to £941k in the year to 30 June 2026, from £784k the year before (+20.1%). But its loss after tax widened to £697k, from £415k.
The report says costs rose faster than sales. It points to one-off costs from a shareholder move to replace the board, heavier use of outside consultants, and the cost of setting up a new statistics service.
The company ended the year with £419k of cash, a little less than a year earlier, and no bank borrowings. It raised £600k by selling new shares and paid no dividend. Looking ahead, the board said it had about £618,000 of contracted work still to deliver, that costs fell significantly in July and August 2026, and that it aims to become profitable as soon as possible. The auditor gave a clean opinion and raised no doubt about the company's ability to keep going, though the report lists raising enough money until it turns a profit as a key risk.
Modelling & Simulation consulting (core service line)
Modelling and Simulation currently remains the primary revenue driver, accounting for 85% of FY26 revenue
page 7One-off costs from Board Requisition/replacement and increased consultant use
Operating loss increased 50% to £687,254 due to one-off costs associated with the Board Requisition and subsequent replacement of the Board, along with increased use of consultants to support revenue generation
page 5The Board believes the Company is entering FY27 from a position of increasing strength... Physiomics has approximately £618,000 of contracted revenue yet to be recognised and a substantial late-stage sales pipeline, providing an encouraging level of visibility for the year ahead
page 9No dividend was paid or proposed. In view of accumulated losses and the Company's stage of development, the Directors are unable to recommend the payment of a dividend
page 2112 years on one page · FY2015–FY2026
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY2023locked | FY202406/24 | FY202506/25 | FY202606/26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Operating profit | ||||||||||||
| Profit for the year | ||||||||||||
| Basic EPS | ||||||||||||
| Free cash flow | ||||||||||||
| Net debt (negative = net cash) | ||||||||||||
| Shares in issue | ||||||||||||
| Operating margin | ||||||||||||
| Return on capital employed |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
Nothing restated
Every figure is read again from the following year’s report: 301 confirmed, 10 differ.
No figure has been restated: every figure a later report printed again, it printed the same.